Clinical Characteristics of Patients With AML Whose Blast Cells Were Treated With MDR1-AS
| Patient . | FAB Subtype . | I/R . | Source of Cell . | WBC (×109/L) . | Blast (%) . | Treatment . | Outcome of Treatment . | P-gp (%) . | MDR1-AS P-gp (%) . | D10 Value (mol/L) . | MDR1-AS D10 Ratio-150 . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | Sex/ Age . | |||||||||||
| 1 | M/47 | M1 | I | P | 400.0 | 98 | BHAC-DMP | NR | 47.0 | 20.9 | 9.0 × 10−7 | 3.3 |
| 2 | F/79 | M1 | I | P | 130.0 | 94 | BHAC-DMP | NR | 54.8 | 14.8 | 2.0 × 10−6 | ND |
| 3 | M/70 | M2 | I | P | 26.0 | 62 | BHAC-DMP | NR | 76.1 | 5.2 | 2.0 × 10−6 | ND |
| 4 | M/47 | M2 | R | B | 437.0 | 75 | BHAC-EM | CR | 34.0 | 10.5 | 2.0 × 10−6 | ND |
| 5 | M/47 | M3 | I | B | 14.1 | 78 | RA, DNR | CR | 33.5 | 4.7 | NE-151 | ND |
| 6 | M/71 | OL-MDS | I | P | 7.2 | 85 | VP, CAG | NR | 26.2 | 4.3 | 1.0 × 10−6 | ND |
| 7 | M/57 | OL-MDS | I | P | 58.0 | 55 | AraC, VP16 | NR | 48.8 | 2.5 | 2.8 × 10−6 | ND |
| 8 | F/61 | CMLbc | I | P | 63.6 | 73 | VP | NE | 49.4 | 19.5 | 6.0 × 10−6 | 3.0 |
| 9 | M/44 | CMLbc | I | P | 49.3 | 60 | AraC, DNR, VCR | NR | 45.8 | 14.8 | 4.0 × 10−6 | 6.4 |
| 10 | M/44 | CMLbc | I | P | 140.0 | 98 | BHAC-DMP | NR | 65.7 | 5.0 | 1.0 × 10−6 | 3.2 |
| Patient . | FAB Subtype . | I/R . | Source of Cell . | WBC (×109/L) . | Blast (%) . | Treatment . | Outcome of Treatment . | P-gp (%) . | MDR1-AS P-gp (%) . | D10 Value (mol/L) . | MDR1-AS D10 Ratio-150 . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | Sex/ Age . | |||||||||||
| 1 | M/47 | M1 | I | P | 400.0 | 98 | BHAC-DMP | NR | 47.0 | 20.9 | 9.0 × 10−7 | 3.3 |
| 2 | F/79 | M1 | I | P | 130.0 | 94 | BHAC-DMP | NR | 54.8 | 14.8 | 2.0 × 10−6 | ND |
| 3 | M/70 | M2 | I | P | 26.0 | 62 | BHAC-DMP | NR | 76.1 | 5.2 | 2.0 × 10−6 | ND |
| 4 | M/47 | M2 | R | B | 437.0 | 75 | BHAC-EM | CR | 34.0 | 10.5 | 2.0 × 10−6 | ND |
| 5 | M/47 | M3 | I | B | 14.1 | 78 | RA, DNR | CR | 33.5 | 4.7 | NE-151 | ND |
| 6 | M/71 | OL-MDS | I | P | 7.2 | 85 | VP, CAG | NR | 26.2 | 4.3 | 1.0 × 10−6 | ND |
| 7 | M/57 | OL-MDS | I | P | 58.0 | 55 | AraC, VP16 | NR | 48.8 | 2.5 | 2.8 × 10−6 | ND |
| 8 | F/61 | CMLbc | I | P | 63.6 | 73 | VP | NE | 49.4 | 19.5 | 6.0 × 10−6 | 3.0 |
| 9 | M/44 | CMLbc | I | P | 49.3 | 60 | AraC, DNR, VCR | NR | 45.8 | 14.8 | 4.0 × 10−6 | 6.4 |
| 10 | M/44 | CMLbc | I | P | 140.0 | 98 | BHAC-DMP | NR | 65.7 | 5.0 | 1.0 × 10−6 | 3.2 |
Abbreviations: M, male; F, female; OL-MDS, overt leukemia from myelodysplastic syndromes; I, initial presentation; R, relapse stage; P, peripheral blood; B, bone marrow; WBC, white blood cell; BHAC, behenoyl AraC; DMP, DNR + 6-mercaptopurine + prednisolone; EM, VP16 + 6-mercaptopurine; RA, retinoic acid; VP, vincristine + prednisolone; CAG, AraC + ACR + G-CSF; VCR, vincristine; CR, complete remission; NR, no response; NE, not evaluable; ND, not done.
The values of D10 ratio in random- and MDR1-S–treated cells were from 0.7 to 1.3, except for MDR1-S–treated cells in case No. 9 (2.2).
This could not be evaluated because only clusters were formed.